FDA
-
-
-
-
-
-
-
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results
-
-
-
-
-
-
-
Sangamo receives FDA fast track designation for pain treatment
-
-
-
-
-
-
-
Sangamo presents data on Fabry disease gene therapy ahead of FDA filing
-
-
-
-
-
-
-
Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease
-
-
-
-
-
-
-
Sangamo BioSciences (SGMO) PT Raised to $10 at H.C. Wainwright
-
-
-
-
-
-
-
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
-
-
-
-
-
-
-
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
-
335,381 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


